Search / 257 results found

from
to
  • Updated

NASHVILLE, Tenn., June 21, 2021 /PRNewswire/ --Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today released a series of case reports describing the effectiveness of Vibativ® (telavancin) in treating secondary bacterial infections in COVID-19 patients – particularly those with other significant health problems, such as obesity, diabetes and heart disease.

  • Updated

DURHAM, N.C., May 26, 2021 /PRNewswire/ -- Inhalon Biopharma, a start-up immunotherapy company developing an inhaled "muco-trapping" antibody platform for treating a variety of acute respiratory infections (ARI), today announced that it has been awarded a $7 million contract by the U.S. Army Medical Research & Development Command (USAMRDC) to conduct a placebo-controlled Phase 1/2a study of IN-006 in COVID-19 outpatients. IN-006 is a potent, neutralizing monoclonal antibody being investigated for the treatment of COVID-19. Initial results of this study are expected in 2022.

  • Updated

NASHVILLE, Tenn., May 11, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and first quarter 2021 financial results. Net revenues from continuing operations during the quarter were $10.5 million, a 26.5% increase over the prior year period. The company also recorded an additional $500,000 in revenue during the first quarter associated with divested product rights for two brands it is no longer distributing.